A new trading day began on Monday, with Arcutis Biotherapeutics Inc (NASDAQ: ARQT) stock price down -4.84% from the previous day of trading, before settling in for the closing price of $13.02. ARQT’s price has ranged from $6.99 to $16.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 379.27% over the past five years. Meanwhile, its annual earnings per share averaged 65.01%. With a float of $103.03 million, this company’s outstanding shares have now reached $117.00 million.
Let’s look at the performance matrix of the company that is accounted for 296 employees. In terms of profitability, gross margin is 89.43%, operating margin of -131.16%, and the pretax margin is -140.72%.
Arcutis Biotherapeutics Inc (ARQT) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 11.97%, while institutional ownership is 103.15%. The most recent insider transaction that took place on Feb 03 ’25, was worth 105,893. In this transaction an insider of this company sold 8,338 shares at a rate of $12.70, taking the stock ownership to the 178,692 shares. Before that another transaction happened on Feb 03 ’25, when Company’s insider sold 19,301 for $12.70, making the entire transaction worth $245,123. This insider now owns 804,129 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.01% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Here are Arcutis Biotherapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) saw its 5-day average volume 1.76 million, a negative change from its year-to-date volume of 2.13 million. As of the previous 9 days, the stock’s Stochastic %D was 65.12%. Additionally, its Average True Range was 1.02.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 53.37%, which indicates a significant increase from 44.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.75% in the past 14 days, which was higher than the 69.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.54, while its 200-day Moving Average is $10.58. Nevertheless, the first resistance level for the watch stands at $12.85 in the near term. At $13.31, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.56. If the price goes on to break the first support level at $12.14, it is likely to go to the next support level at $11.89. The third support level lies at $11.43 if the price breaches the second support level.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
With a market capitalization of 1.45 billion, the company has a total of 117,045K Shares Outstanding. Currently, annual sales are 59,610 K while annual income is -262,140 K. The company’s previous quarter sales were 44,760 K while its latest quarter income was -41,540 K.
